Hubert Yin in his lab at the BioFrontiers Institute (Photo by Glenn Asakawa/CU Boulder)
More than 23.5 million Americans suffer from autoimmune diseases like rheumatoid arthritis, scleroderma and lupus, in which an overzealous immune response leads to pain, inflammation, skin disorders and other chronic health problems. The conditions are so common that three of the top-five selling drugs in the United States aim to ease their symptoms. But no cure exists, and treatments are expensive and come with side effects.
Now CU Boulder researchers have developed a potent, drug-like compound that could someday revolutionize treatment of such diseases by inhibiting a protein instrumental in prompting the body to start attacking its own tissue.
“We have discovered a key to lock this protein in a resting state,” said Hang Hubert Yin, a biochemistry professor in the BioFrontiers Institute and lead author of a paper, published today in Nature Chemical Biology, describing the discovery. “This could be paradigm shifting.”
For years, scientists have suspected that a protein called Toll-like receptor 8 (TLR8) plays a key role in the innate immune response. When it senses the presence of a virus or bacteria, it goes through a series of steps to transform from its passive to active state, triggering a cascade of inflammatory signals to fight off the foreign invader. But, as Yin explained, “it can be a double-edged sword,” leading to disease when that response is excessive.
Because TLR8 has a unique molecular structure and is hidden inside the endosome—an infinitesimal bubble inside the cell—rather than on the cell’s surface, it has proven an extremely difficult target for drug development.
“This is a long-sought-after target with very little success,” Yin said.
But his study shows a drug-like molecule called CU-CPT8m binds to and inhibits TLR8 and exerts “potent anti-inflammatory effects” on the tissue of patients with arthritis, osteoarthritis and Still’s disease, a rare autoimmune illness.
For the study, Yin and his co-authors used high-throughput screening to look through more than 14,000 small molecule compounds to determine whether they had the right chemical structure to bind to TLR8. They identified four that shared a similar structure. Using that structure as a model, they chemically synthesized hundreds of novel compounds in an effort to find one that perfectly bound to and inhibited TLR8.
Previous efforts to target the protein have focused on shutting it down when it is in its active state. But the compound Yin developed prevents it from activating while still in its passive state.
“Before, people were trying to close the open door to shut it down. We found the key to lock the door from the inside so it never opens,” Yin said.
Much more research is necessary, but that could lead to treatments that strike at the root cause of autoimmune diseases, rather than just treating symptoms. With help from CU’s Technology Transfer Office, Yin has already filed a patent application and hopes to move on to animal studies and clinical trials within the next two years.
“Given the prevalence of these diseases, there is a big push for alternatives,” Yin said.
In the meantime, the new compound can serve as a first-of-its kind tool to understand exactly what TLR8 and the other nine toll-like receptors do in the body.
“Our study provides the first small molecule tool to shut this protein down so we can understand its pathogenesis,” Yin said.
Learn more: Arthritis, autoimmune disease discovery could lead to new treatments
The Latest on: Autoimmune diseases
- ADAR1 mutation sets off biochemical pathways that produce an organ-damaging autoimmune responseon August 2, 2022 at 2:03 pm
A new study shows how mutation of the ADAR1 gene sets off biochemical pathways that produce an autoimmune response that harms the developing brain and other areas of the body.
- Nanobody has potential to treat Parkinson's diseaseon August 2, 2022 at 5:00 am
Researchers from Johns Hopkins create a nanobody capable of penetrating brain cells and preventing misshapen proteins from spreading, halting the progression of neurocognitive diseases ...
- AbbVie, Sosei Build In 2020 Pact With New Neurological Disease-Focused Agreementon August 2, 2022 at 3:32 am
Sosei Group Corporation and AbbVie Inc (NYSE: ABBV) announced a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate G ...
- Newly developed nanobodies could eventually be used to treat neurocognitive disorderson August 1, 2022 at 3:52 pm
Proteins called antibodies help the immune system find and attack foreign pathogens. Mini versions of antibodies, called nanobodies — natural compounds in the blood of animals such as llamas and ...
- Dr. Yasmin Mohseni Announces Groundbreaking Treatment for Autoimmune Diseases and Solid Organ Transplantson August 1, 2022 at 10:23 am
Dr. Yasmin Mohseni, an immunologist at USC's Keck School of Medicine who specializes in research and clinical translation of immunotherapeutics, recently announced that companies are pursuing ...
- Zenas BioPharma gets Chinese approval for thyroid eye disease treatment studyon August 1, 2022 at 2:49 am
Zenas BioPharma has received approval from the NMPA in China to start a phase 1/2 clinical study of ZB001 to treat thyroid eye disease.
- Woman describes how she was 'humiliated' at a Walgreens as autoimmune patients become collateral damage in the US abortion crackdownon July 31, 2022 at 5:57 am
Methotrexate, a drug used to treat arthritis, lupus, IBD, and more, is being restricted across the US because it can cause abortions.
- Unraveling key role of astrocytic dopamine receptor D2 in autoimmune disease MSon July 28, 2022 at 6:22 am
In a study published in the Journal of Experimental Medicine, research groups led by Prof. Zhou Jiawei from the Institute of Neuroscience, Center for Excellence in Brain Science and Intelligence ...
- Screenings for Autoimmune Diseases Necessary for Children, Adolescents With T1Don July 21, 2022 at 7:30 am
Current guidelines recommend screening for the 2 most commonly diagnosed autoimmune diseases among adolescent patients with type 1 diabetes, but researchers suggest that additional screenings could ...
- Abortion Laws Deny Treatments Needed for Autoimmune Diseaseon July 21, 2022 at 6:07 am
Methotrexate, a first-line treatment for autoimmune diseases, is being denied to some patients since SCOTUS overturned Roe v Wade.
via Google News and Bing News